Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
0.5600
+0.0291 (+5.48%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
December 23, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 16, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025
Via
ACCESS Newswire
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
November 12, 2025
Via
ACCESS Newswire
Lexaria Attending BIO International Convention
June 05, 2025
Via
ACCESS Newswire
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
February 27, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Provides Strategic Update
October 09, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 29, 2025
Via
ACCESS Newswire
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 26, 2025
Via
ACCESS Newswire
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
September 19, 2025
Via
ACCESS Newswire
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
February 24, 2025
Via
ACCESS Newswire
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
February 20, 2025
Via
ACCESS Newswire
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
February 11, 2025
Via
ACCESS Newswire
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
August 27, 2025
Via
ACCESS Newswire
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
August 14, 2025
Via
ACCESS Newswire
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
August 06, 2025
Via
ACCESS Newswire
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
July 28, 2025
Via
ACCESS Newswire
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
July 23, 2025
Via
ACCESS Newswire
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
February 06, 2025
Via
ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
February 05, 2025
Via
ACCESS Newswire
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
June 23, 2025
Via
ACCESS Newswire
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
June 11, 2025
Via
ACCESS Newswire
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
May 12, 2025
Via
ACCESS Newswire
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
April 28, 2025
Via
ACCESS Newswire
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
April 25, 2025
Via
ACCESS Newswire
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
April 23, 2025
Via
ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
April 03, 2025
Via
ACCESS Newswire
Lexaria's Human GLP-1 Study #5 Begins Dosing
April 02, 2025
Via
ACCESS Newswire
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
March 18, 2025
Via
ACCESS Newswire
Lexaria Releases Annual Letter from the CEO
January 30, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
